- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Concessions improve odds GE will buy Instrumentarium
Strength in patient monitoring remains issue GE's bid to acquire Instrumentarium may be close to reaching approval. The key may be a conciliatory note struck by GE executives regarding concerns by European regulators over the
Strength in patient monitoring remains issue
GE's bid to acquire Instrumentarium may be close to reaching approval. The key may be a conciliatory note struck by GE executives regarding concerns by European regulators over the strength of the combined companies in patient monitoring.
GE has offered, if the deal goes through, to sell Spacelabs Medical, a patient monitoring business unit currently part of Instrumentarium, according to Dow Jones Business News. The company has also agreed to license various patient monitoring and anesthesia technologies. Doing so would improve the competitive position of Spacelabs against major manufacturers of such equipment, including a combined GE-Instrumentarium, as well as Philips and Siemens.
EU regulators objected to the proposed merger primarily on the grounds that a combined GE-Instrumentarium would have too much influence over the prices of patient monitors, according to the wire service. Spearheading the objection was Mario Monti, the European official who engineered the demise of GE's bid to buy Honeywell International two years ago.
European antitrust officials have until Sept. 11 to issue a final decision, but only until Aug. 6 to issue additional objections. The proposed deal must also pass antitrust muster at the U.S. Department of Justice.
Mammography Study Suggests DBT-Based AI May Help Reduce Disparities with Breast Cancer Screening
December 13th 2024New research suggests that AI-powered assessment of digital breast tomosynthesis (DBT) for short-term breast cancer risk may help address racial disparities with detection and shortcomings of traditional mammography in women with dense breasts.
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.
Can MRI-Based AI Bolster Biopsy Decision-Making in PI-RADS 3 Cases?
December 9th 2024In patients with PI-RADS 3 lesion assessments, the combination of AI and prostate-specific antigen density (PSAD) level achieved a 78 percent sensitivity and 93 percent negative predictive value for clinically significant prostate cancer (csPCa), according to research presented at the Radiological Society of North American (RSNA) conference.
Assessing MACE Risk in Women: Can an Emerging Model with SPECT MPI Imaging Have an Impact?
December 9th 2024In research involving over 2,200 women who had SPECT MPI exams, researchers found that those who had a high score with the COronary Risk Score in WOmen (CORSWO) model had a greater than fourfold higher risk of major adverse coronary events (MACE).
